Another potential approach would be to combine a CDK6-selective PROTAC with dexamethasone since the latter was shown to regulate the expression of MYB, BCL2 and BIM in preclinical models of ALL [135]. Here, CDK6 is linked to acute lymphoblastic leukemia.